GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

@article{Gutniak1997GLP1TI,
  title={GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.},
  author={Mark K Gutniak and Hillevi Larsson and Steven W. Sanders and O T Juneskans and Jens Juul Holst and Bo Ahr{\'e}n},
  journal={Diabetes care},
  year={1997},
  volume={20 12},
  pages={1874-9}
}
OBJECTIVE To examine the absorption of glucagon-like peptide (GLP)-1(7-36) amide from the buccal mucosa of type 2 diabetic patients. Previously, the effects of the peptide have been studied following intravenous and subcutaneous injection. Now, a mucoadhesive, biodegradable buccal GLP-1 tablet (9 mm) containing 119 nmol has been developed as a possible alternative to injection. RESEARCH DESIGN AND METHODS A total of 10 type 2 diabetic patients received a single tablet under fasting conditions… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…